Hat den irgenwer auch solche Aktien bekommen? - 500 Beiträge pro Seite

[Bertlk]

Wer weis näheres über diese Aktie ?

[Performancebomber]

Probier`s mal da.

http://www.nasdaq.com/asp/quotes_news.asp?symbol=ONCY%60&sel…

[merx]

Interessanter Artikel aus Calgary Herald :

Cancer patient takes chance on new Calgary treatment

David Heyman
Calgary Herald


Sunday, August 18, 2002

Joan Lisoway

ADVERTISEMENT


Joan Lisoway is used to being first. She was the City of Calgary`s first female draftsman back in 1964, after being the only woman in a drafting class of 50 at the Southern Alberta Institute of Technology.

She and her husband Jim, as Parks Canada surveyors, were likely the first white people to visit a lonely but historic spit of land off Baffin Island in 1972.

Now she`s leading a much more sombre journey. Lisoway, 57, has become the world`s first brain-cancer victim to receive an injection of the highly promising but experimental cancer-fighting drug Reolysin -- based on the benign reovirus whose properties were discovered and patented right here in Calgary.

She agreed to the trial knowing the results may very well benefit others in future years, rather than herself.

"I could help, or not help, but not helping means I would only have a short time to live," says Lisoway, who has undergone five surgeries, several rounds of chemotherapy and radiation treatments since the bright February day in 1999 when she was felled by a surprise grand mal seizure.

In order to be eligible for the trial, she had to have at least one recurrence of the disease after initial conventional treatment, something very common with brain cancer.

But Lisoway rejected a last chemotherapy treatment in order to accept the one-time offer to have a Reolysin injection, which required she not have had a recent intervention. It was a risk she figures was worth taking.

"You always have hope, although there are a number of people I knew (with cancer) who aren`t around anymore."

Hope is at the core of the company behind Reolysin, Oncolytics Biotech Inc. which was formed with the sole intention of developing the treatment into a cancer therapy.

After University of Calgary researcher Patrick Lee discovered the reovirus`s cancer-killing qualities in 1998, he and two of his grad students Matt Coffey and Jim Strong took out the first patent, and then gave it over to Oncolytics the following year to turn into a treatment.

Since then, researchers have found the reovirus is able to kill many kinds of human cancer cells -- including breast, prostate, pancreatic and brain tumours -- without any apparent side effects.

The company has now launched Phase II trials for prostate and Phase I and II trials for brian cancer.

Oncolytics brass know the initial results look good, and they`re optimistic, but they figure they`re still years away from a marketable treatment.

"We`re doing it very quickly, of course. We all want it to go quicker," says Brad Thompson, the CEO of Oncolytics.

© Copyright 2002 Calgary Herald

[merx]

new`s


Dow Jones Business News
Oncolytics Gets Fifth U.S. Patent For Reolysin Tech
Wednesday September 25, 9:06 am ET


CALGARY -(Dow Jones)- Oncolytics Biotech Inc. has been granted a patent covering the use of various strains and combinations of reoviruses, wherein one or more of the reoviruses may be immunoprotected, as a treatment for Ras- mediated proliferative disorders, such as neurofibromatosis and cancer in an immunocompetent mammal.
In a news release, Oncolytics said the patent, U.S. patent 6,455,038, is entitled "Reovirus for the treatment of cellular proliferative disorders."

The biotechnology company said this is its fifth U.S. patent covering Reolysin technology.

Company Web Site: http://www.oncolyticsbiotech.com

-Carolyn King, Dow Jones Newswires; 416-306-2100


Gruß

merx

[merx]

What`s up ????

Hängt es mit eventuell mit dieser Pressemitteilung
zusammen ???

Press Release 06/01/03
BIOVEX ANNOUNCES PRELIMINARY PHASE I DATA ON ONCOVEX GM-CSF IN PATIENTS WITH BREAST CANCER AND MELANOMA


JP Morgan H&Q, San Francisco, 6th January 2003 BioVex announced today preliminary Phase I results from the clinical trial of its lead oncology product candidate, OncoVEX GM-CSF in patients with breast cancer and melanoma.

OncoVEX GM-CSF is the first oncolytic virus (that selectively replicates in and kills tumour cells) containing an immune stimulating factor to enter clinical development. The product is designed to induce both local tumour destruction and a systemic anti-tumour immune response to treat secondary (metastatic tumour) deposits.

Clinical trial design

The primary aim of the clinical trial is to determine safety. In addition, indications of biological activity are determined through the assessment of virus replication, the expression of GM-CSF in the tumour, histological examination of tumour biopsies for evidence of cell necrosis and immune cell infiltration, and gross observation of tumours for signs of tumour destruction.

The study design includes a single dose escalation phase at doses of 106, 107 and 108 virus particles/ml to be given to groups of four patients at each dose to be followed by three repeated injections at the optimal dose in a further group of six patients.

Key findings

After completing the first two dose levels, single injections of OncoVEX GM-CSF into the cutaneous tumour deposits of patients with metastatic cancer have shown that the product

· is well tolerated
· can replicate in the tumour
· causes tumour cells to secrete GM-CSF
· induces tumour necrosis and inflammation

These results show that OncoVEX has considerable anti-tumour activity after only a single low dose. On this basis the Company has concluded that the product should be tested in Phase II clinical trials. The multi dose phase of the existing trial will be used to determine the optimal dose and dosing frequency for use in Phase II. BioVex intends to present the full data at an international cancer conference later in the year.

Enquiries:

Dr.Gareth Beynon, Chief Executive Officer Tel: [phone]
Dr. Colin Love, Director of Product Development Tel: [phone]

Notes to Editors (www.biovex.com)

BioVex is a four year old private biotech company whose principal focus is on the development of therapeutics for cancer and chronic infectious disease. The Company has two unique proprietary product platforms (OncoVEX and ImmunoVEX) and a functional genomics platform (NeuroVEX) all based on the manipulation of the herpes simplex virus (HSV). The Company is headquartered in Oxfordshire with additional laboratory facilities in London.

OncoVEX - the first in a new class of oncolytic cancer vaccines

First generation products, developed by other groups, based on viruses that selectively replicate in and destroy tumour cells without affecting healthy tissue have demonstrated proof of principle in man and have been shown to be well tolerated. BioVex has constructed a series of proprietary "second generation" OncoVEX viruses which are not only more lytic than first generation products but are also designed to stimulate the immune system to destroy metastatic deposits. This has been engineered by the deletion of HSV "immune suppressor genes" and, in the case of its lead product, the insertion of the immune stimulating cytokine gene GM-CSF. OncoVEX GM-CSF is currently undergoing a Phase 1 trial at the Hammersmith Hospital, London.

ImmunoVEX - a unique dendritic cell based vaccine platform

Considerable evidence from advanced clinical trials has shown that antigen presentation by the immune systems key policing cells - dendritic cells - can lead to a therapeutically effective immune response against disease associated antigens to which the body has become tolerant. HSV infects and delivers antigen-encoding genes to dendritic cells at very high efficiency and has the potential to become one of the leading methods for loading these cells with antigens. However, dendritic cells infected with HSV are usually inactivated by the virus. BioVex has identified the genes responsible for this inactivation. The deletion of these genes provides a proprietary vaccine platform which combines very efficient antigen delivery to, and optimal stimulation of, this key class of antigen presenting cell. The Company`s lead programme from the ImmunoVEX platform is in pre-clinical development for the treatment of malignant melanoma.

NeuroVEX

A third platform, NeuroVEX, is dedicated to gene determination in the nervous system.

This news release contains forward-looking statements that reflect the Company`s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein.











top | home
gruß m e r x

[merx]

Reuters
Oncolytics stock up on positive brain cancer data
Monday January 6, 11:33 am ET


TORONTO, Jan 6 (Reuters) - Shares of Oncolytics Biotech (Toronto:ONC.TO - News; NasdaqSC:ONCY - News) jumped by more than a third on Monday, on what company officials and analysts speculated was a delayed reaction to a December announcement that its treatment for brain cancer was well tolerated in five out of six patients.
ADVERTISEMENT


Shares of Oncolytics were up nearly 40 percent in Toronto and 42 percent in the Unites States in the morning. They were up 74 Canadian cents at C$2.63 on the Toronto Stock Exchange and rose 50 cents to $1.69 on Nasdaq.

Oncolytics said on Dec 23 that results from its Phase I trial showed its Reolysin treatment for brain cancer kept five out of six patients alive. The patients had been treated between 10 weeks and 25 weeks.

The Calgary-based company said an independent data safety monitoring board recommended continuing the trial as well as changes to enhance the measurement and efficacy of Reolysin in patients in future studies.

"Nothing really happened to the stock that day. I did not expect anything to happen," said Shameze Rampertab, an analyst with Canaccord Capital, which helped Oncolytics raise C$2 million ($1.3 million) through a share offering in December.

"While (five out of six) is a good number, it is not statistically significant," he added. "This trial needs to come to come to its full conclusion before we can make any kind of speculation on its statistical significance."

Brad Thompson, chief executive of Oncolytics, said: "Some (institutional investors) out of the United States decided to buy the stock on the open market. There is nothing material going on in the company."

($1=$1.56 Canadian)



Gruß

m e r x

[merx]

na, wer hätte das gedacht :

demonstrating lots of demand on volume: triple top breakout: very bullish indicators
ALERT ONC SPREAD TRIPLE TOP BREAKOUT


http://stockcharts.com/def/servlet/SC.pnf?c=ONC.TO,P


happy trades


m e r x

[js200]

Skin Cancer: More than 1 Million New Cases in U.S. This Year

MONDAY, May 26 (HealthScoutNews) -- More than 1 million Americans will learn this year they have skin cancer.
That`s more than twice the number who will hear they have prostate or breast cancer, making skin cancer the most common cancer in the United States.

While prostate and breast cancers kill far more people, skin cancer -- usually caused by excess sun exposure -- can be deadly, too. The American Cancer Society expects about 7,600 deaths this year from melanoma, the most virulent of skin cancers.

Dermatologists like Dr. David J. Goldberg, who practices at the Mt. Sinai School of Medicine in New York City, are worried because their skin cancer patients are younger and younger when first diagnosed.

"I`ve been in practice 17 years," he says. "Seventeen years ago, I saw people in their 50s. Now, I see fair-complected women in their 30s."

As discouraging as the news may sound, there are encouraging developments to note as Americans kick off the unofficial start of summer with Memorial Day.

Blocking out the sun`s harmful rays has never been easier, thanks to new forms of sunblock as well as sun-protective clothing such as hats specially treated to filter the sun.

And, if caught early, skin cancers are highly curable.

Also, new treatments for skin cancer promise to be less disfiguring than surgery but just as effective, cancer experts say.

Fair-skinned, freckled, light-eyed persons who burn easily are most at risk for skin cancer, although others can get it as well. Changes on the skin are the most common warning sign of skin cancer, according to the National Cancer Institute. Not surprisingly, the most common skin cancers -- called basal and squamous cell -- are found mainly on areas often exposed to the sun, such as the face, neck, hands, arms and head.

Melanomas, so named because they develop in the pigment-producing skin cells called melanocytes, are most often found on the trunk of men and the lower legs of women, although they can appear on other sites as well.

Any change on the skin, especially in the color or size of a mole, should be checked by a dermatologist, experts say. The dermatologist may then decide to biopsy the area, taking a small sample of skin to examine it under a microscope for cancerous or pre-cancerous cells.

Standard treatments include removing the cancer with surgery, laser therapy, radiation or chemotherapy drugs in lotion or cream form applied to the skin, experts say.

A newer approach, says Goldberg, is photodynamic therapy. First, a light-activated drug that targets cancer cells is applied or injected. A day or so later, a laser light is aimed at the cancerous tissue and "switches on" the drug, which destroys the cancer cells but does not affect healthy cells, he says.

So far, the approach is only approved by the U.S. Food and Drug Administration for treating other forms of cancer -- such as esophageal cancer -- and for pre-cancerous skin lesions. But some doctors are now trying it for skin cancers.

Another new approach being tested for some skin cancers is a so-called immune modifier, says Dr. Martin A. Weinstock, a professor of dermatology at Brown University and chairman of the American Cancer Society`s skin cancer advisory group. A drug called imiquimod (Aldara) is applied topically; it works by triggering an immune response, causing the body to attack the malignant cells, he says.

Increasingly, doctors are also using digital photography to monitor people with suspected melanomas, to track and quantify how much the growth changes from visit to visit.

Even with these advances, Weinstock says, "the most important thing people can do is look carefully at their skin once a month."

An annual skin exam by your physician or dermatologist is also wise, says Dr. Diane Berson, an assistant professor of dermatology at the Weill Medical College of Cornell University in New York City and a spokeswoman for the American Academy of Dermatology. It`s crucial, she says, if you have a family history of skin cancer or are at high risk.

Sunblocks are also vital, and an array of new products is making it easier to follow that recommendation, says Goldberg. Sunblocks and screens now come not only in cream form but gels and sprays, minimizing the "ick" factor of greasy creams. Clothing specially treated with sunblocking agents can help, too.

Despite all that has been said about skin cancer and the need for sunscreens, some people still don`t bother to read the directions or know how to use the products properly, Goldberg says. Among the most common mistakes: People wait to apply a sunscreen after they`ve gone outdoors.

"Put it on a half hour before you go out," he says. And use a product with a sun protective factor (SPF) of at least 15. "And reapply SPF 15 every two hours," Goldberg adds.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/23/2003 (12:53 ET) New 6-K just released for ONCY - Edgar



05/23/2003 (11:21 ET) 52W HIGH: New 52-Wk High for ONCY @ $2.260 up7.62% - Knobias



05/22/2003 (13:19 ET) Oncolytics Biotech narrows Q1 net loss to $1.1M from nearly $1.3 M last year - The Canadian Press (AP)



05/22/2003 (13:19 ET) Oncolytics Biotech narrows Q1 net loss to $1.1M from nearly $1.3 M last year - The Canadian Press (AP)



05/22/2003 (12:17 ET) Oncolytics Biotech narrows Q1 net loss to $1.1M from nearly $1.3 M last year - The Canadian Press (AP)



05/22/2003 (12:17 ET) Oncolytics Biotech narrows Q1 net loss to $1.1M from nearly $1.3 M last year - The Canadian Press (AP)



05/22/2003 (12:13 ET) Oncolytics Biotech narrows Q1 net loss to $1;1M from nearly $1;3 M last year - The Canadian Press (AP)



05/22/2003 (12:12 ET) Oncolytics Biotech narrows Q1 net loss to $1;1M from nearly $1;3 M last year - The Canadian Press (AP)



05/22/2003 (09:36 ET) ERN(-): ONCY/Q1 5c vs 7c; EPS -29% Y/Y; No Guidance - Knobias



05/22/2003 (08:31 ET) Oncolytics Biotech announces 2003 first quarter results - Canada NewsWire



05/22/2003 (08:31 ET) Oncolytics Biotech announces 2003 first quarter results - PR Newswire



05/21/2003 (11:45 ET) New 6-K just released for ONCY - Edgar



05/21/2003 (08:32 ET) Oncolytics Biotech Inc. Announces Issuance of Seventh U.S. Patent - Canada NewsWire



05/21/2003 (08:30 ET) Oncolytics Biotech Inc. Announces Issuance of Seventh U.S. Patent - PR Newswire



05/20/2003 (08:02 ET) CONF: ONCY To Present At Techvest European Conference @ 02:40 ET - Knobias



05/19/2003 (12:21 ET) 52W HIGH: New 52-Wk High for ONCY @ $2.190 up24.43% - Knobias



05/13/2003 (10:17 ET) 6-K: ONCY Vote; Dir; Auditor; Stock Op Plan; Prvt Place - Knobias



05/13/2003 (08:08 ET) New 6-K just released for ONCY - Edgar



05/08/2003 (07:03 ET) Oncolytics Biotech resumes enrollment in phase I malignant glioma study - Datamonitor



05/07/2003 (15:28 ET) New 6-K just released for ONCY - Edgar



05/07/2003 (11:16 ET) VOLUME(-): ONCY Volume 14% > 20-adsv, Stock -3.89% - Knobias



05/07/2003 (08:31 ET) Oncolytics Biotech Inc. Reports Enrollment Has Resumed In Phase I Malignant Glioma Study - Canada NewsWire



05/07/2003 (08:30 ET) Oncolytics Biotech Inc. Reports Enrollment Has Resumed In Phase I Malignant Glioma Study - PR Newswire



05/06/2003 (10:06 ET) VOLUME(+): ONCY Volume 30% > 20-adsv, Stock +12.36% - Knobias



05/05/2003 (10:48 ET) VOLUME(+): ONCY Volume 14% > 20-adsv, Stock +7.14% - Knobias

JS200